Abstract 1044
Background
Brain metastases (BM) from colorectal cancer (CRC) are rare and usually develop late in the disease. However, it has been suggested that more patients will be diagnosed with BM from CRC due to improved diagnostics and increased survival. The aim of this study was to identify biological and clinical characteristics that could predict later BM development in long surviving patient with metastatic (m) CRC.
Methods
We retrospectively reviewed a multicenter database and biobank encompassing consecutive patients with mCRC who all received cetuximab in combination with irinotecan as third-line treatment independently of RAS status between 2005 and 2008. We performed RAS (KRAS & NRAS), BRAF, and PIK3CA sequencing of DNA from primary tumor tissue.
Results
Totally, 480 patients were included in the study. BM were diagnosed in 42 patients (8.8 %) at median 29 months after mCRC diagnosis. Patient characteristics are shown in table 1. Patients with BM had a significantly longer survival from mCRC diagnosis than non-BM patients (32 months vs 28 months, p = 0.001). On univariate cox regression analysis the risk of developing BM was increased in patients with rectal cancer (Hazard ratio (HR) = 2.478, p = 0.005), metachronous metastatic disease (HR = 2.296, p = 0.013), and lung metastases at mCRC diagnosis (HR = 4.196, p
Conclusions
The incidence of BM was 8.8 % in our cohort of long surviving patients with mCRC. Having lung metastases at mCRC diagnosis seems to be an independent risk factor for later BM development. Rectal cancer and metachronous metastatic disease were also linked to an increased risk of BM.
Patient characteristics
| -BM 438 patients | +BM 42 patients | |
|---|---|---|
| Median age at CRC diagnosis | 60 years | 58 years |
| Rectal cancer | 153 (35 %) | 26 (62 %) |
| Metachronous metastatic disease | 188 (43 %) | 28 (67 %) |
| Lung metastases | 130 (30 %) | 26 (62 %) |
| RAS Mut | 184 (42 %) | 20 (48 %) |
| BRAF Mut | 30 (7 %) | 0 |
| PIK3CA Mut | 58 (13 %) | 7 (16 %) |
Clinical trial identification
Legal entity responsible for the study
Troels Dreier Christensen and Dorte Lisbet Nielsen
Funding
The Danish Cancer Society
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract